Amag Pharmaceuticals (AMAG) 27.02 $AMAG How These

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amag Pharmaceuticals (AMAG) 27.02 $AMAG

How These Healthcare Stocks are Performing? -- AMAG Pharma, IDEXX Laboratories, Neogenomics, and ICON
PR Newswire - Fri Jul 29, 7:50AM CDT
The Healthcare sector remains one of the most stable industries in the market, unfazed by economic conditions and uncertainties. While the industry faces issues with cost pressures, ransomware risks, and existing policies, several companies remain unscathed and continue to impress with significant returns. Stocks to evaluate today on Stock-Callers.com are AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), Neogenomics Inc. (NASDAQ: NEO), and ICON PLC (NASDAQ: ICLR). Learn more about these stocks by accessing their free notes at:
NEO: 8.52 (-0.20), AMAG: 27.02 (+0.49), IDXX: 93.51 (-0.28), ICLR: 76.97 (-0.70)

AMAG Pharmaceuticals Shares Up 17.6% Since SmarTrend's Buy Recommendation (AMAG)
Comtex SmarTrend(R) - Wed Jul 27, 1:06AM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on May 31st, 2016 at $21.22. In approximately 2 months, AMAG Pharmaceuticals has returned 17.58% as of today's recent price of $24.95.
AMAG: 27.02 (+0.49)

AMAG Pharmaceuticals Shares Up 20.3% Since SmarTrend's Buy Recommendation (AMAG)
Comtex SmarTrend(R) - Tue Jul 12, 1:27AM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on May 31st, 2016 at $21.22. In approximately 1 month, AMAG Pharmaceuticals has returned 20.26% as of today's recent price of $25.52.
AMAG: 27.02 (+0.49)

Should You Get Rid of AMAG Pharmaceuticals (AMAG) Now?
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:54AM CDT
AMAG Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
ANIP: 61.06 (+0.46), AMAG: 27.02 (+0.49)

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire - Wed May 25, 7:08AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will discuss AMAG's business and financial outlook, strategy and growth prospects at the following investor conferences taking place in June 2016.
AMAG: 27.02 (+0.49)

Why Investors Still See Value in Alkermes, AMAG Pharmaceuticals, IDEXX Laboratories and Atossa Genetics?
PR Newswire - Thu May 19, 7:50AM CDT
The equities market is never short of surprises, and one sector that is always abounding of surprises is without doubt the Healthcare space. ActiveWallSt.com has uncovered four stocks in the Healthcare sector ahead of today's trading session: Alkermes PLC (NASDAQ: ALKS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Atossa Genetics Inc. (NASDAQ: ATOS). Sign up for your complimentary alerts at:
ATOS: 0.27 (+0.02), AMAG: 27.02 (+0.49), IDXX: 93.51 (-0.28), ALKS: 49.56 (-0.34)

New Strong Sell Stocks for May 19th
Swarup Gupta - Zacks Investment Research - Thu May 19, 7:45AM CDT
5 fresh stock additions to the Zacks Rank #5 (Strong Sell) List for Thursday
UEPS: 10.14 (-0.20), PLM: 0.74 (-0.01), MTGE: 16.47 (+0.11), WY: 32.75 (+0.03), AMAG: 27.02 (+0.49)

AMAG Pharmaceuticals Announces 2016 Analyst Day
GlobeNewswire - Thu May 19, 7:00AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), a specialty pharmaceutical company with a diverse portfolio of products in the areas of maternal health, anemia management and cancer supportive care, today announced that it will host an Analyst Day in New York City on Wednesday, June 1, 2016. The event will start at 8:30 a.m. and conclude at approximately 12:00 p.m. ET.
AMAG: 27.02 (+0.49)

AMAG Pharmaceuticals Has Returned 19.3% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Wed May 18, 1:21AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on May 3rd, 2016 at $23.23. In approximately 2 weeks, AMAG Pharmaceuticals has returned 19.29% as of today's recent price of $18.75.
AMAG: 27.02 (+0.49)

Downgrade Alert for AMAG Pharmaceuticals (AMAG)
Comtex SmarTrend(R) - Thu May 05, 3:36AM CDT
AMAG Pharmaceuticals (NASDAQ:AMAG) was downgraded from Outperform to Market Perform at Raymond James today. The stock closed yesterday at $19.55 on volume of 4.3 million shares, above average daily volume of 1.0 million. AMAG Pharmaceuticals share prices have moved between a 52-week high of $77.73 and a 52-week low of $20.22 and closed yesterday at -3% above that low price at $19.55 per share. Over the past week, the 200-day moving average (MA) has gone down 2.2% while the 50-day MA has declined 0.7%.
AMAG: 27.02 (+0.49)

AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 6:00AM CDT
-- First quarter 2016 non-GAAP product revenue increased 52% to $117.6 million
AMAG: 27.02 (+0.49)

AMAG Pharmaceuticals to Participate in the Deutsche Bank 41st Annual Healthcare Conference
GlobeNewswire - Wed Apr 27, 7:02AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in an analyst-led fireside chat at the Deutsche Bank 41 Annual Healthcare Conference on Wednesday, May 4, 2016 at 8:40 a.m. ET in Boston.
DB: 13.07 (-0.37), AMAG: 27.02 (+0.49)

AMAG Pharmaceuticals to Host Conference Call on May 3, 2016 at 8:00 a.m. ET to Discuss Financial Results for the First Quarter Ended March 31, 2016
GlobeNewswire - Thu Apr 21, 7:03AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it will report unaudited consolidated financial results for the first quarter ended March 31, 2016 before the U.S. financial markets open on Tuesday, May 3, 2016. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET, during which management will provide an update on recent developments and discuss the company's first quarter 2016 financial and operating results.
AMAG: 27.02 (+0.49)

Gilead Presents Multiple HCV and HBV Data at Liver Congress
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 12:59PM CDT
Gilead Sciences (GILD) presented results from several phase II and phase III studies for the treatment of HCV and HBV infection at The International Liver Congress.
EBS: 30.97 (-2.42), GILD: 80.46 (+0.99), AMAG: 27.02 (+0.49), ANIK: 50.64 (+0.72)

Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 10:30AM CDT
Synta (SNTA) announced all-stock merger transaction with Madrigal Pharmaceuticals to create a company focused on cardiovascular-metabolic diseases and NASH.
SNTA: 0.34 (+0.07), EBS: 30.97 (-2.42), ICPT: 169.72 (-3.31), AMAG: 27.02 (+0.49)

Intrexon (XON) Gains Following Deals with Two Startups
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 2:40PM CDT
Intrexon's (XON) shares gained after the company announced exclusive channel collaborations with a couple of Harvest Intrexon Enterprise Fund-backed startups.
EBS: 30.97 (-2.42), FCSC: 1.02 (-0.07), XON: 27.38 (+2.05), AMAG: 27.02 (+0.49)

Merck Offers Positive Data from Comparative Trial on Zepatier
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 10:20AM CDT
Merck (MRK) announced results from a phase III study which compared Zepatier to a regimen of Gilead's Sovaldi plus peginterferon and ribavirin.
EBS: 30.97 (-2.42), GILD: 80.46 (+0.99), MRK: 58.66 (unch), AMAG: 27.02 (+0.49)

Arena (ARNA) Gains, Pain Drug Positive in Early Stage Study
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 12:00PM CDT
Arena (ARNA) announced favorable results from a phase Ib study on its pain candidate, APD371.
EBS: 30.97 (-2.42), AMAG: 27.02 (+0.49), ANIK: 50.64 (+0.72), ARNA: 1.68 (+0.01)

Repros Reveals Positive Data on Proellex for Uterine Fibroids
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 11:30AM CDT
Repros (RPRX) reported positive data from a phase IIb study on Proellex (vaginal administration) for the treatment of women suffering from uterine fibroids.
EBS: 30.97 (-2.42), RPRX: 2.06 (-0.06), AMAG: 27.02 (+0.49), ANIK: 50.64 (+0.72)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 211

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
NeuroPace Faces Investigation After Revenue Forecast Cut

Updated Category News Views 35

NeuroPace Revenue Drama: A Blow to Investor Confidence How the mighty have stumbled—or so it feels to the folks who put their bucks into NeuroPace, Inc. (NASDAQ: NPCE). It's tough to swallow: they cut their 2026 revenue forecast from a hopeful $99.5-$101.5 million to a sobering $91-$92 million. Just one quarter apart those projections are, like a cruel twist of fate...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 155

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
AppLovin Faces Legal Heat: Investors on Edge Today

Updated Category News Views 104

AppLovin's Day of Reckoning: Investors Take Note Ever find yourself caught in a whirlwind of corporate promises that slide into disappointment? Well, buckle up, because that's exactly where AppLovin finds itself today. They've stirred up a storm with investors over some questionable hyperbole about their artificial intelligence tools and ad services. Missteps and Market...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 189

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 123

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 68

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Operation Healing Forces Partners with Wounded Warrior

Updated Category News Views 56

Joining Forces for Special Operations Families When it comes to the heavy lifting of supporting Special Operations Forces (SOF) families, two powerhouses—Operation Healing Forces (OHF) and Wounded Warrior Project (WWP)—are doubling down. They’re not just tossing around good intentions. Oh no, they’re pulling out the stops with a solid partnership focused on...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 126

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 142

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Nauticus Robotics Reports Exciting Q3 2025 Financial Results

Updated Category News Views 251

Nauticus Robotics Shows Strong Performance in Q3 2025 Nauticus Robotics, Inc. (NASDAQ: KITT), an industry leader in subsea robotics, has recently made headlines with their impressive financial performance during the third quarter of 2025. This period marked a remarkable increase in customer interest, innovative capabilities, and upcoming product launches that promise to...

Continue Reading
Nano Labs' Strategic Move to Nasdaq Global Market: Key Benefits

Updated Category News Views 152

Nano Labs Elevates to Nasdaq Global Market Nano Labs Ltd (Nasdaq: NA), a frontrunner in Web 3.0 infrastructure and product solutions, has officially announced its uplisting to the Nasdaq Global Market. This significant move is designed to provide enhanced opportunities for growth and stability, marking an exciting chapter for the company and its shareholders. Impact of...

Continue Reading
The EVERY Company Strengthens Its Patent Portfolio in Europe

Updated Category News Views 169

The EVERY Company Enhances Its Intellectual Property The EVERY Company, a prominent innovator in protein ingredients, has recently secured a significant patent for its recombinant ovalbumin in the European Union. This development consolidates its position as a leader in crafting functional protein ingredients, paving the way for its growth and expansion within the global...

Continue Reading
Discover the Compounding Success of Analog Devices Over a Decade

Updated Category News Views 204

How $100 Invested in Analog Devices Transformed Over 10 Years Analog Devices (NASDAQ: ADI) has had a remarkable journey over the past decade, outperforming the market with an annualized growth of 2.67%, resulting in an impressive average annual return of 14.15%. As of the latest figures, Analog Devices boasts a market capitalization of approximately $118.16 billion. The...

Continue Reading
Mustang Bio Secures $8 Million in Public Offering Success

Updated Category News Views 118

Mustang Bio Completes $8 Million Public Offering Mustang Bio, Inc. (Nasdaq: MBIO), a prominent company in the biopharmaceutical sector, renowned for its innovative cell therapies, recently announced the successful closure of a public offering that raised approximately $8 million. This financial milestone signifies a major step forward for the company as it aims to drive...

Continue Reading